Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research Article

Clinical Relevance of Tumor Markers for the Control of Chemotherapy

J. FINEK, L. HOLUBEC, O. TOPOLCAN, J. SALVET, R. PIKNER, S. HOLDENRIEDER, P. STIEBER, R. LAMERZ, L. HOLUBEC SEN., S. SVOBODOVA, V. VISOKAI and E. HELMICHOVA
Anticancer Research May 2005, 25 (3A) 1655-1658;
J. FINEK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: finek{at}fnplzen.cz
L. HOLUBEC JR.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. TOPOLCAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. SALVET
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. PIKNER 1
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. HOLDENRIEDER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. STIEBER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. LAMERZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. HOLUBEC SEN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. SVOBODOVA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. VISOKAI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. HELMICHOVA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

This presentation is based on our experience with tumor marker monitoring of surgery therapy and chemotherapy effects. The control of chemotherapy is one of the most important problems in oncological practice. The correlation between the clinical status of the patient and tumor size changes, based on the results of different imaging methods, has been the most important and most frequently used method. However, the therapy effect has been recently assessed by markers of the biological activity of the tumor. Using tumor markers for the assessment of the effect of surgery therapy is already part of routine practice in many different types of cancer. Pre-operative and post-operative values of tumor markers are essential for a proper evaluation. However, tumor marker monitoring of the effect of radiotherapy and chemotherapy has been used very rarely, mostly only for research purposes. Besides monitoring by classical tumor markers, monitoring by markers of angiogenesis and apoptosis seem to be promising for the assessment of chemotherapy effect. Measurement of circulating cancer cells by means of mRNA also seems to be intriguing for therapy effect control and monitoring of the course of disease. Unfortunately, the routine use of these methods has been applied in only a few institutes worldwide. A completely different situation has been observed in palliative treatment. In most cases, changes of serum levels of tumor markers correlate with therapy effect. Thus, the effect of treatment on tumor proliferation can be successfully estimated by decreasing tumor marker levels.

  • Chemotherapy control
  • biological markers
  • colorectal cancer
  • breast cancer
  • ovarian cancer
  • Received September 13, 2004.
  • Revision received February 2, 2005.
  • Accepted February 16, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 25, Issue 3A
1 May 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Relevance of Tumor Markers for the Control of Chemotherapy
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Clinical Relevance of Tumor Markers for the Control of Chemotherapy
J. FINEK, L. HOLUBEC, O. TOPOLCAN, J. SALVET, R. PIKNER, S. HOLDENRIEDER, P. STIEBER, R. LAMERZ, L. HOLUBEC SEN., S. SVOBODOVA, V. VISOKAI, E. HELMICHOVA
Anticancer Research May 2005, 25 (3A) 1655-1658;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Clinical Relevance of Tumor Markers for the Control of Chemotherapy
J. FINEK, L. HOLUBEC, O. TOPOLCAN, J. SALVET, R. PIKNER, S. HOLDENRIEDER, P. STIEBER, R. LAMERZ, L. HOLUBEC SEN., S. SVOBODOVA, V. VISOKAI, E. HELMICHOVA
Anticancer Research May 2005, 25 (3A) 1655-1658;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire